Daito Pharmaceutical Co., Ltd.

As of May 31, 2025, Daito Pharmaceutical Co., Ltd. carries a market capitalization of 29.54B, placing it among publicly traded companies globally. Its enterprise value stands at 39.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Daito Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for January 8, 2027.

As of May 31, 2025, Daito Pharmaceutical Co., Ltd. has 29.99M shares outstanding.

These figures are as of May 31, 2025.

As of May 31, 2025, Daito Pharmaceutical Co., Ltd. maintains a current ratio of 2.45, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended May 31, 2025.

Over the twelve months ended May 31, 2025, Daito Pharmaceutical Co., Ltd. recorded an income tax benefit of -130.00M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Daito Pharmaceutical Co., Ltd.'s stock has gained approximately 7.40% over the past 52 weeks. The 50-day moving average sits at 1,322.44, while the 200-day moving average is 1,322.23.

As of May 31, 2025, Daito Pharmaceutical Co., Ltd. holds 2.21B in cash and equivalents against 11.89B in total debt, resulting in a net debt position of 7.46B. Total book value stands at 52.00B, with working capital of 24.66B providing operational flexibility.

Daito Pharmaceutical Co., Ltd.'s most recent stock split took place on May 29, 2025 with a 1:2 split ratio.